Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
119 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Alcohol Addiction - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Alcohol Addiction - Pipeline Review, H1 2015', provides an overview of the Alcohol Addiction's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Alcohol Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alcohol Addiction and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Alcohol Addiction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Alcohol Addiction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Alcohol Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Alcohol Addiction pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alcohol Addiction - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alcohol Addiction pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Alcohol Addiction Overview 10 Therapeutics Development 11 Pipeline Products for Alcohol Addiction - Overview 11 Pipeline Products for Alcohol Addiction - Comparative Analysis 12 Alcohol Addiction - Therapeutics under Development by Companies 13 Alcohol Addiction - Therapeutics under Investigation by Universities/Institutes 16 Alcohol Addiction - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Alcohol Addiction - Products under Development by Companies 20 Alcohol Addiction - Products under Investigation by Universities/Institutes 22 Alcohol Addiction - Companies Involved in Therapeutics Development 23 AbbVie Inc. 23 Addex Therapeutics Ltd 24 Adial Pharmaceuticals, LLC 25 Astraea Therapeutics, LLC 26 AstraZeneca PLC 27 Bionex Pharmaceuticals LLC 28 Curemark, LLC 29 D&A Pharma SAS 30 Eli Lilly and Company 31 Euthymics Bioscience, Inc. 32 Foresee Pharmaceuticals, LLC 33 Heptares Therapeutics Ltd. 34 Johnson & Johnson 35 Kyorin Pharmaceutical Co., Ltd. 36 Lohocla Research Corporation 37 Omeros Corporation 38 Pfizer Inc. 39 SK Biopharmaceuticals Co., Ltd. 40 Sun Pharma Advanced Research Company Ltd. 41 Tekmira Pharmaceuticals Corp. 42 Tonix Pharmaceuticals Holding Corp. 43 VM Discovery, Inc. 44 Zynerba Pharmaceuticals, Inc. 45 Alcohol Addiction - Therapeutics Assessment 46 Assessment by Monotherapy Products 46 Assessment by Combination Products 47 Assessment by Target 48 Assessment by Mechanism of Action 50 Assessment by Route of Administration 52 Assessment by Molecule Type 54 Drug Profiles 56 (disulfiram + selegiline) - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 (topiramate + ondansetron hydrochloride) - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 ABT-436 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 ADX-71441 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 amitifadine - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Antisense Gene Therapy for Alcoholism - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 baclofen ER - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 carisbamate - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 CM-1212 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Drug to Inhibit Triple Reuptake for Alcohol Dependence - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Drugs to Activate HAT for CNS Disorders - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Drugs to Inhibit Histone Deacetylase for CNS Disorders - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 FP-007 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 GET-73 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 ibudilast - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 JNJ-31020028 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 JNJ-5234801 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 LY-2940094 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 naltrexone - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 naltrexone - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 OMS-405 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 OMS-527 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 ondansetron hydrochloride - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 PF-04457845 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 saracatinib difumarate - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 SLV-330 - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 Small Molecule for Central Nervous System - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 Small Molecule to Antagonize Ghrelin for Alcoholism - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse and Alcohol Addiction - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 Small Molecule to Antagonize Orexin 1 for Addiction and Compulsive Disorders - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 Small Molecules to Agonize NOP for Pain - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 sodium oxybate IR - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 TKM-ALDH2 - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 VMD-2202 - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 Alcohol Addiction - Recent Pipeline Updates 97 Alcohol Addiction - Dormant Projects 106 Alcohol Addiction - Discontinued Products 108 Alcohol Addiction - Product Development Milestones 109 Featured News & Press Releases 109 Jan 07, 2015: Addex and NIAAA Enter Collaboration to Evaluate ADX71441 in Alcohol Use Disorder 109 Apr 30, 2014: ADial Pharmaceuticals Announces Issuance of First U.S. Patent 109 Nov 04, 2013: Clinical Trial Indicates Gabapentin Is Safe and Effective for Treating Alcohol Dependence 110 Oct 10, 2013: Tekmira Provides Corporate Update on TKM-ALDH2 112 Aug 25, 2013: National Institute on Alcohol Abuse and Alcoholism Funds New UCLA Clinical Trial of MediciNova's MN-166 in Treating Alcoholism 113 Aug 12, 2013: ADial Pharmaceuticals Announces Publication of Study on AD04 for the Treatment of Patients With Alcohol Use Disorder 113 Aug 09, 2013: Curemark wins patent for CM-1212 to treat drug, alcohol addiction 114 May 21, 2013: Addex Validates Potential Efficacy Biomarker For Phase I Trial Of ADX71441 115 Apr 30, 2013: Addex Therapeutics Reports ADX71441 Reduces Alcohol Intake In Preclinical Model Of Chronic Alcohol Dependence 115 Apr 18, 2013: ADial Pharma Announces Agreement With FDA For Phase III Trial Of AD04 For Alcohol Use Disorder In Patients Of Targeted Genotypes 116 Appendix 118 Methodology 118 Coverage 118 Secondary Research 118 Primary Research 118 Expert Panel Validation 118 Contact Us 118 Disclaimer 119
List of Tables Number of Products under Development for Alcohol Addiction, H1 2015 11 Number of Products under Development for Alcohol Addiction - Comparative Analysis, H1 2015 12 Number of Products under Development by Companies, H1 2015 14 Number of Products under Development by Companies, H1 2015 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H1 2015 16 Comparative Analysis by Late Stage Development, H1 2015 17 Comparative Analysis by Clinical Stage Development, H1 2015 18 Comparative Analysis by Early Stage Development, H1 2015 19 Products under Development by Companies, H1 2015 20 Products under Development by Companies, H1 2015 (Contd..1) 21 Products under Investigation by Universities/Institutes, H1 2015 22 Alcohol Addiction - Pipeline by AbbVie Inc., H1 2015 23 Alcohol Addiction - Pipeline by Addex Therapeutics Ltd, H1 2015 24 Alcohol Addiction - Pipeline by Adial Pharmaceuticals, LLC, H1 2015 25 Alcohol Addiction - Pipeline by Astraea Therapeutics, LLC, H1 2015 26 Alcohol Addiction - Pipeline by AstraZeneca PLC, H1 2015 27 Alcohol Addiction - Pipeline by Bionex Pharmaceuticals LLC, H1 2015 28 Alcohol Addiction - Pipeline by Curemark, LLC, H1 2015 29 Alcohol Addiction - Pipeline by D&A Pharma SAS, H1 2015 30 Alcohol Addiction - Pipeline by Eli Lilly and Company, H1 2015 31 Alcohol Addiction - Pipeline by Euthymics Bioscience, Inc., H1 2015 32 Alcohol Addiction - Pipeline by Foresee Pharmaceuticals, LLC, H1 2015 33 Alcohol Addiction - Pipeline by Heptares Therapeutics Ltd., H1 2015 34 Alcohol Addiction - Pipeline by Johnson & Johnson, H1 2015 35 Alcohol Addiction - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 36 Alcohol Addiction - Pipeline by Lohocla Research Corporation, H1 2015 37 Alcohol Addiction - Pipeline by Omeros Corporation, H1 2015 38 Alcohol Addiction - Pipeline by Pfizer Inc., H1 2015 39 Alcohol Addiction - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 40 Alcohol Addiction - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015 41 Alcohol Addiction - Pipeline by Tekmira Pharmaceuticals Corp., H1 2015 42 Alcohol Addiction - Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2015 43 Alcohol Addiction - Pipeline by VM Discovery, Inc., H1 2015 44 Alcohol Addiction - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2015 45 Assessment by Monotherapy Products, H1 2015 46 Assessment by Combination Products, H1 2015 47 Number of Products by Stage and Target, H1 2015 49 Number of Products by Stage and Mechanism of Action, H1 2015 51 Number of Products by Stage and Route of Administration, H1 2015 53 Number of Products by Stage and Molecule Type, H1 2015 55 Alcohol Addiction Therapeutics - Recent Pipeline Updates, H1 2015 97 Alcohol Addiction - Dormant Projects, H1 2015 106 Alcohol Addiction - Dormant Projects (Contd..1), H1 2015 107 Alcohol Addiction - Discontinued Products, H1 2015 108
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
